UA122678U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography. In the serum determine the polymorphism of the gene MTHFR C677T, the content of thrombomodulin, cobalamin, PSA, TGF- (1, with homozygous carrier 677-TT, thrombomodulin levels> 5 ng / ml, cobalamin <300 ng / ml, PSA> 6 mg / ml, PSA TGF- (1 <14 ng / ml diagnose the development of atherosclerosis.

Description

The useful model belongs to medicine, in particular to therapy and rheumatology and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (AN Okorokov.

Diagnosis of diseases of internal organs. - Vol. 6 - pp. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that along with the study of low and high density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of thrombomodulin, cobalamin, C-reactive protein (CRP), transforming growth factor beta 1 ( TFR-RD1).

With homozygous carrier 677-TT, levels of thrombomodulin "5 ng/ml, cobalamin "300 ng/ml,

SRP "6 mg/l, TFR-R1 "14 ng/ml diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. The polymorphism of the MTNEK C677T gene is determined in the patient's blood serum. The content of thrombomodulin, cobalamin, SRP, TFR-B1I is determined by immunoenzymatic method. With homozygous carrier 677-TT, levels of thrombomodulin "5 ng/ml, cobalamin "300 ng/ml, SRP "b mg/l, TFR-DVI1 "14 ng/ml diagnose the development of atherosclerosis.

A specific example of using the method.

Patient V., 56 years old, was hospitalized with a diagnosis of rheumatoid arthritis. Inspected.

Low and high density lipoprotein cholesterol levels were studied. Vascular arteriography was performed. There are no signs of atherosclerosis. The MTNEK C677T gene polymorphism was determined in blood serum. The content of thrombomodulin, cobalamin,

SRP, TFR-DR1. Homozygous carrier 677-TT was established. Levels of thrombomodulin - 9.6 ng/ml, cobalamin - 195 ng/ml, SRP - 16 mg/l, TGF-VD1I - 6.5 ng/ml. Diagnosed development

From atherosclerosis. Arteriographic signs of atherosclerosis were established only after 8 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages of the process.

Claims (1)

USEFUL MODEL FORMULA The method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of the levels of low and high-density lipoprotein cholesterol, arteriography, which is distinguished by the fact that the MTNEVK C677T gene polymorphism, the content of thrombomodulin, cobalamin, SRP, TGF-RI, in homozygous carrier 677 are determined in the blood serum -TT, thrombomodulin levels 25 ng/ml, cobalamin "300 ng/ml, PSA "6 mg/l, TFR-DI1 "14 ng/ml diagnose the development of atherosclerosis.